Allianz SE Boosts Stake in Eli Lilly and Company $LLY

Allianz SE grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,499 shares of the company’s stock after acquiring an additional 1,298 shares during the quarter. Eli Lilly and Company comprises 0.7% of Allianz SE’s portfolio, making the stock its 24th biggest position. Allianz SE’s holdings in Eli Lilly and Company were worth $31,570,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after acquiring an additional 682,203 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter valued at $4,613,912,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. UBS Group increased their target price on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. BMO Capital Markets upped their price target on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $981.89.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,018.28 on Thursday. The stock has a market cap of $962.67 billion, a P/E ratio of 66.55, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50 day moving average of $815.33 and a 200-day moving average of $778.16. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,022.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the firm earned $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.